IHE - Gunnel Ragnarson Tennvall

Publiceringar IHE Information IHE Forum IHEs Nätverk för hälsoekonomer Kurser i hälsoekonomi

Institutet för Hälso- och
Sjukvårdsekonomi
Box 2127
SE-220 02 Lund
Besök: Råbygatan 2
Tel: 046-32 91 00
info@ihe.se

Gunnel Ragnarson Tennvall

dr i medicinsk vetenskap | projektledare

Arbetsområden

Gunnel Ragnarson Tennvall har 20 års erfarenhet av hälsoekonomiskt analysarbete. Hennes forskning är inriktad mot hälsoekonomiska analyser av läkemedel och annan medicinsk teknologi. Flertalet projekt genomförs i samarbete med kliniskt verksamma forskare. Gunnel disputerade vid medicinska fakulteten vid Lunds universitet 2001 med avhandlingen “The Diabetic foot – Costs, health economic aspects, prevention and quality of life”.

Pågående och nyligen avslutade projekt inkluderar analys av registerdata avseende hematologisk sjukdom och endometrios. Utvärdering och analys av interventioner för olika dermatologiska sjukdomar är andra aktuella arbetsområden. Andra intresseområden är mätning av livskvalitet och QALYs.

Gunnel har medverkat som hälsoekonom i arbetet med Socialstyrelsens Nationella riktlinjer för prostatacancer- och bröstcancersjukvård som publicerades 2007. Sedan 2001 är Gunnel medlem i EURODIALE, en europeisk forskargrupp inriktad på studier av diabetiker med fotkomplikationer.

Sjukdomsområden:
       • Dermatologi
       • Diabetes
       • Hematologi
       • Onkologi
       • Parkinsons sjukdom

Urval av publiceringar

Hjortsberg C, Bergman A, Bjarnsson A, Heikkilä H, Hjelmgren J, Svensson Å & Tennvall Ragnarson G
Are Treatment Satisfaction, Quality of Life, and Self-assessed Disease Severity Relevant Parameters for Patient Registries? Experiences from Finnish and Swedish Patients with Psoriasis
Acta Derm Venereol 2011; 91: 409–414

Hjalte F, Asseburg C, Tennvall G R
Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden - with model applications for Denmark, Norway and Finland
Journal of the European Academy of Dermatology and Venereology, JEADV, 2010; 24(4): 474-480

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Tennvall GR, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, Van Baal J, Van Merode F & Schaper N.
Delivery of care to diabetic patients with foot ulcers in daily practice: results of the Eurodiale Study, a prospective cohort study
Diabetic Medicine 2008; 25: 700-707

Prompers L, Huijberts M, Schaper N, Apelqvist J, Bakker K, Edmonds M, Holstein P, Jude E, Jirkovska A, Mauricio D, Piaggesi A, Reike H, Spraul M, Van Acker K, Van Baal S, Van Merode F, Uccioli L, Urbancic V & Ragnarson Tennvall G.
Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study
Diabetologia 2008; 51:1826-1834

Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, Uccioli L, Urbancic V, Bakker K, Holstein P, Jirlovska A, Piaggesi A, Ragnarson Tennvall G, Reike H, Spraul M, Van Acker K, Van Baal J, Van Merode F, Ferreira I, and Huijberts M.
Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE study
Diabetologia 2008; 51 (5): 747-755

Hjelmgren J, Svensson Å, Jörgensen ET, Lindemalm-Lundstam B & Ragnarson Tennvall G
Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data
British Journal of Dermatology (BJD) 2007; 156 (5): 913-921.
Erratum (BJD) 2008; 159: 994-995.

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal S, van Merode F & Schaper N.
High prevalence of ischemia, infection and serious co-morbidity in patients with diabetic foot disease in Europe. Baseline results from the EURODIALE study
Diabetologia 2007; 50 (1): 18-25

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Tennvall GR, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal J, van Merode F & Schaper N.
Optimal organization of health care in diabetic foot disease: introduction to the Eurodiale study
Int J Low Extrem Wounds 2007; 6 (1): 11-17

Ragnarson Tennvall G, Hjelmgren J & Öien R
The cost of treating hard-to-heal venous leg ulcers: results from a Swedish survey
World Wide Wounds, 2006, November.
www.worldwidewounds.com

Ragnarson Tennvall G, Hjelmgren J & Malmberg L
Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms?
Scandinavian Journal of Urology and Nephrology 2006;40:495-505

Boulton A J M, Vileikyte L, Ragnarson Tennvall G & Apelqvist J. The global burden of diabetic foot disease. Lancet 2005; 366(12):1719-24.

Ragnarson Tennvall G & Hjelmgren J. Behandling av venösa bensår, kostsamt för sjukvård och samhälle. Läkartidningen 2005; 102(42): 3027-3029.

Hjelmgren J, Persson U & Ragnarsson Tennvall G. Local treatment pattern versus trial-based data: A cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden. American Journal of Therapeutics 2005; 12(5): 425-430.

Ragnarson Tennvall G. Economic factors. In Bakker K, Foster A, van Houtum W, Riley P (Eds). Put feet first prevent amputations. Diabetes and foot care. IDF, International Diabetes Federation, Brussels, 2005.

Ragnarson Tennvall G & Hjelmgren J. Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom.
Wound Repair and Regeneration 2005;13 (1):13-18.

Ragnarson Tennvall G & Apelqvist J. Health economic consequences of diabetic foot lesions. Clinical Infectious Diseases 2004;39: S132-9.

Ragnarson Tennvall G, Andersson K, Bjellerup M, Hjelmgren J & Öien R. Venösa bensår kan behandlas både bättre och billigare. Beräkning av årliga kostnader baserad på en enkätstudie. Läkartidningen 2004; 101: 1506-1513.

Fyhr, A., Jendteg, S., Ragnarson Tennvall, G., Cavallin-Ståhl, E. & Wain, R. Costs of preparing cytotoxic drugs by nurses on hospital wards or by pharmcists in preparation centres. Journal of Social and Administrative Pharmacy 2001:18(5);193-197.

Ragnarson Tennvall G. The diabetic foot – Costs, health economic aspects, prevention, and quality of life. Doktorsavhandling, Lunds Universitet, 2000.

Ragnarson Tennvall G & Apelqvist J. Prevention of diabetes-related foot ulcers and amputations – A cost-utility analysis based on Markov model simulations. Diabetologica 2001:44;2007-2087.

Ragnarson Tennvall G, Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. Journal of Diabetes and Its Complications 2000: 14; 235-241.

Ragnarson Tennvall G, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics, 2000: 18(3); 225-238

Ragnarson Tennvall G, Apelqvist J, Eneroth M. The inpatient care of patients with diabetes mellitus and foot ulcers. A validation study of the correspondence between medical records and the Swedish Inpatient Registry with the consequences for cost estimations. Journal of Internal Medicine 2000: 248; 397-405.